Table 1

Baseline characteristics of patients in the 2-year analysis populations in RA-BEYOND

Baseline characteristicsRA-BEGIN
DMARD-naïve
RA-BEAM
MTX-IR
RA-BUILD
csDMARD-IR
MTXBari 4 mgBari 4 mg+MTXPlaceboBari 4 mgADAPlaceboBari 2 mgBari 4 mg
N=138N=121N=151N=361N=385N=263N=157N=165N=152
Age, years49.9 (12.9)51.0 (12.8)47.5 (13.4)52.3 (11.5)52.9 (11.8)52.7 (11.9)51.9 (12.3)52.1 (12.1)52.3 (11.5)
Female, n (%)97 (70.3)90 (74.4)108 (71.5)280 (77.6)301 (78.2)200 (76.0)132 (84.1)130 (78.8)124 (81.6)
White, n (%)82 (59.4)76 (62.8)86 (57.0)223 (61.9)243 (63.1)161 (61.2)113 (72.0)115 (69.7)99 (65.6)
Duration of RA*, years, median0.20.20.26.45.65.83.03.44.5
Swollen joint count, of 6615.6 (10.1)15.3 (8.6)16.2 (9.5)14.8 (8.5)14.9 (8.4)15.0 (8.7)13.0 (6.7)†13.1 (8.0)13.4 (7.2)
Tender joint count, of 6826.7 (15.1)24.8 (12.7)27.9 (14.5)22.6 (13.0)23.2 (12.9)22.8 (13.6)24.5 (15.0)†22.1 (13.7)23.1 (13.6)
CDAI38.88 (12.54)38.74 (12.58)40.65 (13.13)37.00 (12.47)37.73 (12.07)37.39 (13.05)35.89 (11.72)35.47 (12.85)35.73 (11.86)
SDAI41.09 (12.92)41.20 (13.50)43.19 (13.62)38.82 (12.67)39.99 (12.80)39.54 (13.42)37.55 (11.89)37.23 (13.22)37.12 (12.20)
HAQ-DI1.64 (0.66)1.60 (0.74)1.62 (0.67)1.50 (0.68)1.55 (0.68)1.54 (0.70)1.51 (0.60)1.48 (0.62)1.48 (0.61)
DAS28-hsCRP5.86 (0.92)5.83 (0.98)5.95 (0.92)5.64 (0.92)5.74 (0.93)5.71 (0.95)5.56 (0.87)5.49 (0.95)5.49 (0.90)
Corticosteroid use† n (%)55 (39.9)35 (28.9)61 (40.4)224 (62.0)217 (56.4)154 (58.6)78 (49.7)91 (55.2)73 (48.0)
  • Data reported as mean (SD) unless otherwise indicated.

  • *Time from RA diagnosis.

  • †At time of first baricitinib dose.

  • ADA, adalimumab; Bari, baricitinib; CDAI, Clinical Disease Activity Index; csDMARD-IR, inadequate responders to conventional synthetic DMARDs; DAS28-hsCRP, Disease Activity Score modified to include the 28 diarthrodial joint count based on the hsCRP level; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire–Disability Index; hsCRP, high-sensitivity C-reactive protein; MTX, methotrexate; MTX-IR, inadequate responders to methotrexate; n, number of patients in indicated category; N, number of patients in the analysis population; RA, rheumatoid arthritis; SDAI, Simplified Disease Activity Index.